Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
This report delivers a deep-dive analysis of Hanmi Pharmaceutical, one of South Korea’s leading pharmaceutical companies, covering not only financial and clinical data, but also the structural intelligence behind its strategic moves.
Using the BBIU (Business, Biotech & Institutional Understanding) methodology, the dossier translates Hanmi’s Q1 2025 performance into actionable insights across:
Competitive Positioning: From national manufacturer to global player, leveraging its cardiovascular blockbusters and long-acting drug platform (LAPSCOVERY®).
Governance & Leadership: Family succession dynamics and the consolidation of management under the new generation.
Financial Overview: Q1 2025 results with USD conversion, including revenue breakdown, exports, and R&D spending.
Pipeline & Clinical Trials: Seven active trials across oncology, metabolic diseases, and rare conditions — including the high-profile immuno-oncology collaboration with Merck.
Regulatory Landscape: Anticipatory regulatory strategy, multinational trial execution, and alignment with global agencies.
Manufacturing & Supply Chain: The Paltan Smart Plant, API vertical integration via Hanmi Fine Chemical, and expansion of Beijing Hanmi.
Partnerships & Alliances: Symbiotic collaborations with Merck and regional partners, plus licensing history.
Risk & Scenario Outlook: Clinical, financial, and geopolitical risks mapped with early warning signals and future scenarios.
📌 Who is this report for?
Institutional investors
Strategic pharma executives
Policy makers and healthcare analysts
This dossier is designed to provide clarity, foresight, and strategic interpretation for decision-makers who need more than just numbers — a structural understanding of Hanmi’s place in the evolving biopharmaceutical ecosystem.
This report delivers a deep-dive analysis of Hanmi Pharmaceutical, one of South Korea’s leading pharmaceutical companies, covering not only financial and clinical data, but also the structural intelligence behind its strategic moves.
Using the BBIU (Business, Biotech & Institutional Understanding) methodology, the dossier translates Hanmi’s Q1 2025 performance into actionable insights across:
Competitive Positioning: From national manufacturer to global player, leveraging its cardiovascular blockbusters and long-acting drug platform (LAPSCOVERY®).
Governance & Leadership: Family succession dynamics and the consolidation of management under the new generation.
Financial Overview: Q1 2025 results with USD conversion, including revenue breakdown, exports, and R&D spending.
Pipeline & Clinical Trials: Seven active trials across oncology, metabolic diseases, and rare conditions — including the high-profile immuno-oncology collaboration with Merck.
Regulatory Landscape: Anticipatory regulatory strategy, multinational trial execution, and alignment with global agencies.
Manufacturing & Supply Chain: The Paltan Smart Plant, API vertical integration via Hanmi Fine Chemical, and expansion of Beijing Hanmi.
Partnerships & Alliances: Symbiotic collaborations with Merck and regional partners, plus licensing history.
Risk & Scenario Outlook: Clinical, financial, and geopolitical risks mapped with early warning signals and future scenarios.
📌 Who is this report for?
Institutional investors
Strategic pharma executives
Policy makers and healthcare analysts
This dossier is designed to provide clarity, foresight, and strategic interpretation for decision-makers who need more than just numbers — a structural understanding of Hanmi’s place in the evolving biopharmaceutical ecosystem.